Eton Pharmaceuticals Inc

B. Riley analyst Mayank Mamtani has identified six top biotech picks heading into third-quarter 2026 earnings season, following the Federal Reserve's 25 basis point rate hike to 4.00%, its first increase since July 2023. The unanimous 12-0 vote left room for one to two additional hikes before year-end, and with the 10-year Treasury at its highest level since 2007, small and mid-cap biotech stocks face a macro-driven drawdown that historically has presented buying opportunities. The XBI index is up 27% year-to-date but down 2% quarter-to-date, compared to the S&P 500's 13% and 4% gains respectively, while loss of exclusivity-driven pharma mergers and acquisitions track toward their strongest year since 2019, permanent FDA leadership is installed, and drug-pricing risk is largely resolved through most favored nation agreements covering 26 companies. Late third quarter and fourth quarter carry over 40 company-specific catalysts across the coverage list. The picks are Axsome Therapeutics, rated Buy with a $300 price target and up 6% year-to-date, where the analyst models AUVELITY revenue at approximately $205 million to $210 million against consensus of $215.8 million and total revenue of approximately $259 million; Cytokinetics, rated Buy with a $146 price target and up 4% year-to-date, with MYQORZO wholesale tracking to approximately $18 million for the full third quarter versus $8.9 million for all of second quarter; Eton Pharmaceuticals, rated Buy with a $70 price target and up 229% year-to-date, with consensus third-quarter 2026 and fiscal year 2026 revenue of $42 million and $149.7 million versus management's guidance of over $145 million for fiscal year 2026; Harrow, rated Buy with a $60 price target and down 31% year-to-date, with fiscal year 2026 guidance of $350 million to $365 million; TG Therapeutics, rated Buy with an $86 price target and up 95% year-to-date, positioned to compound off an approximately $1 billion U.S. Briumvi exit run-rate at year-end 2026; and Zymeworks, rated Buy with a $44 price target and up 4% year-to-date, where partner Jazz Pharmaceuticals' third-quarter 2026 report in early November provides the first commercial read on the first-line HER2-positive gastroesophageal adenocarcinoma launch following the August 25 approval and $250 million milestone.

Eton Pharmaceuticals stock surged 41.9% through 2:15 p.m. ET Friday after the rare-disease drug developer reported second-quarter results that beat analyst forecasts and raised its full-year guidance. The company posted a profit of $0.43 per share on $37.6 million in sales, compared with Wall Street expectations of $0.15 per share on $26.9 million in revenue. Sales nearly doubled year over year, and Eton flipped from a $0.10 per share GAAP loss to a $0.35 per share profit. The company also licensed the rights to infantile hemangioma drug candidate ASN-001 from Auson Pharmaceuticals, and raised its revenue guidance to exceed $145 million for the year, well above the $121 million analysts had expected.

Eton Pharmaceuticals shares rallied 25% in premarket trading on Friday after the company reported record quarterly revenue and issued 2026 guidance exceeding $145 million with an adjusted EBITDA margin target above 35%. CEO Sean Brynjelsen highlighted significant margin expansion and progress across the commercial portfolio and pipeline, along with several strategic transactions to support long-term growth. The company reiterated a net realized price of $8,000 to $10,000 for HEMANGEOL and said commercial focus is shifting to volume growth and converting patients from off-label adult product use. Eton Pharmaceuticals stock is up over 140% year to date.

Five biotech stocks highlighted in RTTNews reports have delivered gains ranging from 100% to over 300% since their respective publication dates. Climb Bio Inc. rose 310% to $12.90 from a published price of $3.14 on December 15, 2025, driven by pipeline progress and positive early clinical data for Budoprutug and CLYM116. Tectonic Therapeutic Inc. gained 121% to $37.93 from $17.15 on October 27, 2025, following positive Phase 1b results for TX45 and initiation of multiple clinical trials. UroGen Pharma Ltd. climbed 280% to $38.02 from $10.01 on April 25, 2025, after FDA approval of Zusduri and strong revenue growth. Eton Pharmaceuticals Inc. advanced 128% to $37.50 from $16.44 on December 11, 2025, supported by FDA approval of DESMODA and multiple commercial deals. Liquidia Corp. surged 249% to $78.93 from $22.59 on October 17, 2025, fueled by the launch and expanding adoption of Yutrepia.